NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Oncotelic Therapeutics and Sapu Bioscience's Landmark Review on Sub-15 nm Nanoparticles for Drug Delivery
TL;DR
Oncotelic Therapeutics' sub-15 nm nanoparticles offer a competitive edge by overcoming delivery limitations of existing therapies, potentially leading to more effective cancer treatments.
The review details how sub-15 nm nanoparticles achieve deeper tissue penetration, reduced organ accumulation, and enhanced diffusion across biological barriers including the blood-brain barrier.
This nanoparticle technology could significantly improve cancer treatment outcomes and quality of life for patients by enabling more targeted, less toxic therapeutic delivery.
Oncotelic's breakthrough research explores nanoparticles smaller than 15 nm, a size range that could revolutionize how medicines are delivered throughout the human body.
Found this article helpful?
Share it with your network and spread the knowledge!
The review article comprehensively examines nanoparticles exclusively within the 5-15 nm range, defining this emerging scale as a new frontier in drug delivery that could redefine nanomedicine.
These nanoparticles achieve deeper tissue penetration, reduced organ accumulation, faster renal clearance, and enhanced diffusion across biological barriers including the blood-brain barrier, overcoming delivery and toxicity limitations of both small molecules and larger nanocarriers.
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and their joint venture partner Sapu Bioscience collaborated on this landmark review article.
The article was published in the International Journal of Molecular Sciences (IJMS 2025, 26, 10842) and is available at https://doi.org/10.3390/ijms262210842.
They provide superior tissue penetration, reduced organ accumulation, faster clearance from the body, and better diffusion across biological barriers compared to both small molecules and larger nanocarriers.
The paper was authored by Dr. Tapas De, Vuong Trieu, Scott Myers, Sanjive Qazi, Saran Saund, and Cynthia Lee.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products, particularly for high-unmet-need cancers and rare pediatric indications.
The latest news and updates relating to OTLC are available in the company's newsroom at https://nnw.fm/OTLC.
This is the first comprehensive review to examine nanoparticles exclusively within the 5-15 nm range, establishing this size regime as a new pharmacological paradigm for drug delivery.
Beyond its internal programs, Oncotelic licenses and codevelops drug candidates through joint ventures, including owning 45% of GMP Bio, a joint venture advancing complementary drug candidates in oncology and rare disease therapeutics.
Curated from InvestorBrandNetwork (IBN)
